Addex Total Stockholder Equity vs Cash Analysis
ADXN Stock | USD 8.71 0.09 1.04% |
Addex Therapeutics financial indicator trend analysis is way more than just evaluating Addex Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Addex Therapeutics is a good investment. Please check the relationship between Addex Therapeutics Total Stockholder Equity and its Cash accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Addex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide.
Total Stockholder Equity vs Cash
Total Stockholder Equity vs Cash Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Addex Therapeutics Total Stockholder Equity account and Cash. At this time, the significance of the direction appears to have totally related.
The correlation between Addex Therapeutics' Total Stockholder Equity and Cash is 0.99. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Cash in the same time period over historical financial statements of Addex Therapeutics, assuming nothing else is changed. The correlation between historical values of Addex Therapeutics' Total Stockholder Equity and Cash is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of Addex Therapeutics are associated (or correlated) with its Cash. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash has no effect on the direction of Total Stockholder Equity i.e., Addex Therapeutics' Total Stockholder Equity and Cash go up and down completely randomly.
Correlation Coefficient | 0.99 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Cash
Cash refers to the most liquid asset of Addex Therapeutics, which is listed under current asset account on Addex Therapeutics balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Addex Therapeutics customers. The amounts must be unrestricted with restricted cash listed in a different Addex Therapeutics account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.Most indicators from Addex Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Addex Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Addex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide.At this time, Addex Therapeutics' Enterprise Value Over EBITDA is very stable compared to the past year. As of the 29th of November 2024, Enterprise Value Multiple is likely to grow to 0.01, while Selling General Administrative is likely to drop about 4.7 M.
Addex Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Addex Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Addex Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 33.0M | 20.2M | 22.5M | 8.3M | 4.6M | 4.4M | |
Other Current Liab | 2.0M | 1.3M | 1.9M | 1.6M | 1.2M | 1.2M | |
Total Current Liabilities | 5.7M | 3.6M | 4.1M | 3.3M | 2.9M | 4.0M | |
Total Stockholder Equity | 25.5M | 14.6M | 16.9M | 4.9M | 1.1M | 1.1M | |
Property Plant And Equipment Net | 571.0K | 633.1K | 542.1K | 398.7K | 352.9K | 335.3K | |
Current Deferred Revenue | 212.7K | 1.1M | 820.1K | 235.0K | 270.2K | 412.9K | |
Net Debt | (31.0M) | (18.1M) | (20.0M) | (6.6M) | (3.5M) | (3.7M) | |
Retained Earnings | (300.8M) | (313.7M) | (329.1M) | (349.9M) | (360.4M) | (378.4M) | |
Accounts Payable | 2.2M | 983.5K | 1.8M | 1.3M | 984.4K | 913.8K | |
Cash | 31.5M | 18.7M | 20.5M | 7.0M | 3.9M | 3.7M | |
Non Current Assets Total | 639.9K | 692.2K | 600.0K | 453.1K | 407.3K | 386.9K | |
Non Currrent Assets Other | 68.9K | 59.1K | 57.9K | 54.4K | 54.3K | 51.6K | |
Cash And Short Term Investments | 31.6M | 18.8M | 20.5M | 7.0M | 3.9M | 3.7M | |
Common Stock Shares Outstanding | 26.4M | 26.7M | 34.1M | 45.2M | 74.3M | 78.0M | |
Liabilities And Stockholders Equity | 33.0M | 20.2M | 22.5M | 8.3M | 4.6M | 4.4M | |
Other Current Assets | 734.0K | 661.2K | 1.1M | 270.4K | 217.0K | 206.2K | |
Other Stockholder Equity | 286.4M | 280.8M | 272.3M | 327.9M | 329.9M | 288.2M | |
Total Liab | 7.5M | 5.6M | 5.6M | 3.4M | 3.5M | 4.5M | |
Property Plant And Equipment Gross | 571.0K | 633.1K | 4.3M | 4.4M | 4.7M | 2.4M | |
Total Current Assets | 32.4M | 19.5M | 21.9M | 7.8M | 4.2M | 4.0M | |
Short Term Debt | 373.0K | 308.6K | 287.7K | 286.1K | 274.0K | 193.4K | |
Non Current Liabilities Total | 1.8M | 2.0M | 1.5M | 87.0K | 603.1K | 761.6K | |
Accumulated Other Comprehensive Income | 7.1M | 8.6M | 24.4M | 25.8M | 29.8M | 31.3M | |
Net Receivables | 118.0K | 68.4K | 324.4K | 598.3K | 151.3K | 271.7K | |
Other Liab | 639.4K | 1.6M | 1.7M | 1.3M | 1.5M | 813.2K | |
Net Tangible Assets | 25.5M | 14.6M | 16.9M | 4.9M | 5.6M | 5.4M | |
Other Assets | 68.9K | 59.1K | 57.9K | 54.4K | 48.9K | 66.0K | |
Short Term Investments | 14.0K | 64.9K | 17.1K | 3.2K | 848.0 | 805.6 | |
Property Plant Equipment | 571.0K | 633.1K | 542.1K | 398.7K | 458.5K | 275.1K | |
Net Invested Capital | 25.5M | 14.6M | 16.9M | 4.9M | 1.1M | 1.1M | |
Net Working Capital | 26.7M | 15.9M | 17.8M | 4.5M | 1.3M | 1.3M |
Pair Trading with Addex Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Addex Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Addex Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Addex Stock
0.63 | VTRS | Viatris | PairCorr |
0.58 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
0.45 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
0.36 | WAT | Waters | PairCorr |
0.32 | GILD | Gilead Sciences | PairCorr |
The ability to find closely correlated positions to Addex Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Addex Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Addex Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Addex Therapeutics to buy it.
The correlation of Addex Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Addex Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Addex Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Addex Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Addex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Addex Therapeutics. If investors know Addex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Addex Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (21.66) | Revenue Per Share 1.2 | Quarterly Revenue Growth (0.82) | Return On Assets (0.62) | Return On Equity (1.26) |
The market value of Addex Therapeutics is measured differently than its book value, which is the value of Addex that is recorded on the company's balance sheet. Investors also form their own opinion of Addex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Addex Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Addex Therapeutics' market value can be influenced by many factors that don't directly affect Addex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Addex Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Addex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Addex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.